Welcome to our dedicated page for Aptorum Group SEC filings (Ticker: APM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering if Aptorum’s latest clinical trial milestone affects valuation or whether new shares are hitting the market? This dedicated Aptorum Group SEC filings hub brings every disclosure into one place and turns dense biotech language into clear insights.
Use Stock Titan’s AI-powered summaries to move straight to the numbers that matter: R&D spending, cash runway, and pipeline updates buried deep in the Aptorum Group annual report 10-K simplified or the Aptorum Group quarterly earnings report 10-Q filing. Real-time alerts flag Aptorum Group Form 4 insider transactions real-time so you can track executive stock moves before the market reacts. Our platform also connects each Aptorum Group 8-K material events explained with context on clinical partnerships, capital raises, and licensing deals.
Need hard data fast? Skip scrolling through EDGAR and head straight to:
- 10-K & 10-Q for detailed pipeline timelines, trial costs, and dilution analysis—perfect for “Aptorum Group earnings report filing analysis”.
- Form 4 for “Aptorum Group executive stock transactions Form 4” and “Aptorum Group insider trading Form 4 transactions”.
- DEF 14A proxy for “Aptorum Group proxy statement executive compensation”.
- 8-K updates on strategic collaborations, drug approvals, or adverse events.
Whether you’re understanding Aptorum Group SEC documents with AI for the first time or comparing quarter-over-quarter progress, Stock Titan keeps you ahead with expert analysis, complete coverage, and filing-time alerts that land seconds after EDGAR posts.
Savers Value Village, Inc. (SVV) filed a Form 144 indicating that an insider intends to sell up to 600 common shares through Fidelity Brokerage Services on or after 22 Jul 2025. Based on the reference price in the notice, the stake is valued at $6,306. With 157,451,564 shares outstanding, the proposed sale equals roughly 0.0004 % of the float, implying negligible market impact.
The seller, identified in the three-month sales table as Richard Medway, has already disposed of 36,513 shares between May and July 2025 for gross proceeds of about $402 k. The 600 shares originate from a stock option granted 12 Jun 2019 and exercised for cash on the planned sale date.
This filing is routine compliance with Rule 144 for restricted/control securities. Given the de-minimis size relative to daily volume and market cap, the event is unlikely to influence valuation, though investors may note the ongoing insider selling trend.
FAQ
What is the current stock price of Aptorum Group (APM)?
What is the market cap of Aptorum Group (APM)?
What is the primary focus of Aptorum Group Ltd?
How does the company drive its drug discovery efforts?
What are the key business segments of Aptorum Group Ltd?
Which therapeutic areas are emphasized by Aptorum Group Ltd?
How is Aptorum Group Ltd positioned within the competitive pharmaceutical landscape?
Does the company engage in activities outside of traditional drug development?
How does Aptorum Group Ltd ensure the credibility of its research?
